Harrow to buy Melt Pharmaceuticals

Harrow (NASDAQ:HROW [https://seekingalpha.com/symbol/HROW]) to acquire [https://seekingalpha.com/pr/20245629-harrow-to-acquire-melt-pharmaceuticals] Melt Pharmaceuticals, a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings.

The closing of this acquisition is subject to customary closing conditions, including approval by Melt stockholders, excluding Harrow and Harrow-affiliated parties.

Melt’s lead investigational therapy, MELT-300, is a patented, sublingually delivered formulation of a fixed dose of midazolam (3mg) and ketamine (50mg) developed to provide rapid, predictable sedation and analgesia without the need for intravenous administration.

The MELT 300 product candidate has patents issued in North America, Australia, Europe, Asia, and the Middle East. Harrow intends to identify suitable development and commercialization partners to make this technology available outside the U.S. market.

MORE ON HARROW HEALTH

* Harrow: Buy A Blend Of Value And Growth [https://seekingalpha.com/article/4822496-harrow-buy-a-blend-of-value-and-growth]
* Harrow: A Classical GARP Stock [https://seekingalpha.com/article/4821055-harrow-a-classical-garp-stock]
* Harrow Baby Bonds Yield Review [https://seekingalpha.com/article/4815824-harrow-baby-bonds-yield-review]
* Harrow launches $250M debt offering [https://seekingalpha.com/news/4493008-harrow-launches-250m-debt-offering]
* Harrow announces leadership changes, Andrew Boll to serve as President and CFO [https://seekingalpha.com/news/4488677-harrow-announces-leadership-changes-andrew-boll-to-serve-as-president-and-cfo]